Disc Medicine, Inc. (NASDAQ:IRON) is MPM Bioimpact LLC’s 7th Largest Position

MPM Bioimpact LLC increased its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 11.1% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 346,401 shares of the company’s stock after acquiring an additional 34,640 shares during the period. Disc Medicine comprises approximately 3.1% of MPM Bioimpact LLC’s portfolio, making the stock its 7th largest position. MPM Bioimpact LLC owned about 1.16% of Disc Medicine worth $21,962,000 as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in IRON. Tower Research Capital LLC TRC boosted its holdings in shares of Disc Medicine by 47.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock worth $52,000 after purchasing an additional 266 shares during the period. Teacher Retirement System of Texas raised its stake in Disc Medicine by 8.9% in the fourth quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company’s stock worth $308,000 after buying an additional 396 shares in the last quarter. Sterling Capital Management LLC raised its stake in Disc Medicine by 798.4% in the fourth quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock worth $36,000 after buying an additional 503 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Disc Medicine by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,310 shares of the company’s stock worth $400,000 after buying an additional 593 shares in the last quarter. Finally, MetLife Investment Management LLC increased its stake in shares of Disc Medicine by 6.6% during the fourth quarter. MetLife Investment Management LLC now owns 12,132 shares of the company’s stock valued at $769,000 after purchasing an additional 755 shares in the last quarter. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IRON has been the subject of a number of analyst reports. Morgan Stanley reaffirmed an “overweight” rating and set a $85.00 target price on shares of Disc Medicine in a research note on Friday, March 7th. BMO Capital Markets raised their target price on shares of Disc Medicine from $112.00 to $120.00 and gave the company an “outperform” rating in a research note on Monday. Scotiabank raised their target price on shares of Disc Medicine from $73.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, March 3rd. Stifel Nicolaus raised their target price on shares of Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a research note on Friday, January 24th. Finally, Cantor Fitzgerald increased their price target on shares of Disc Medicine from $99.00 to $132.00 and gave the company an “overweight” rating in a report on Tuesday, March 18th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Disc Medicine presently has a consensus rating of “Buy” and a consensus price target of $98.80.

Insider Transactions at Disc Medicine

In other news, insider William Jacob Savage sold 2,100 shares of the firm’s stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $50.17, for a total transaction of $105,357.00. Following the sale, the insider now directly owns 66,398 shares in the company, valued at $3,331,187.66. This trade represents a 3.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Jonathan Yen-Wen Yu sold 1,610 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total transaction of $87,873.80. Following the sale, the chief operating officer now owns 40,555 shares in the company, valued at $2,213,491.90. The trade was a 3.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 356,290 shares of company stock worth $19,336,901 in the last 90 days. 4.24% of the stock is currently owned by insiders.

Disc Medicine Price Performance

Shares of Disc Medicine stock opened at $46.35 on Wednesday. The company’s fifty day simple moving average is $46.54 and its 200-day simple moving average is $54.93. The stock has a market capitalization of $1.60 billion, a PE ratio of -11.65 and a beta of 0.77. Disc Medicine, Inc. has a 1-year low of $30.65 and a 1-year high of $68.73.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.03). As a group, research analysts anticipate that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.